Amalgamated Financial’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Amalgamated Financial’s Portfolio SEEL Stock Details SEEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$13K	Buy	+4	New	+$17.2K	﹤0.01%	2853

Other funds holding SEEL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UIC

Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Amalgamated Financial's SEEL Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Seelos Therapeutics, Inc. Common Stock (SEEL) in Q1 2022: 4 shares worth $13K. The stake represents ﹤0.01% of the portfolio and ranks #2853 among its holdings.

77 funds tracked by Wall St. Rank hold SEEL as of Q1 2022.

Amalgamated Financial held 4 shares of Seelos Therapeutics, Inc. Common Stock worth $13K as of Q1 2022.
Seelos Therapeutics, Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
Seelos Therapeutics, Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2853 holding.
77 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.